source
- Novartis to buy Myricx Bio for up to $1.5 billion, adding two novel ADCs to its oncology portfolioNovartis announced it will acquire Myricx Bio, a UK‑based biotech that develops antibody drug conjugates (ADCs), in a move to broaden its oncology pipeline. The transaction is valued at up to $1.5…
- CMS proposes rule to slash Medicare 340B drug payments by over a thirdCMS announced a proposed rule that would reduce the rates Medicare uses to reimburse hospitals for drugs purchased through the 340B program. The reduction would be more than one-third, effectively…